What is Inflection Biosciences?
Inflection Biosciences Ltd is an early-stage drug development firm specializing in the discovery and creation of novel small molecule therapeutics. The company's focus areas encompass oncology, autoimmune disorders, and inflammatory diseases, addressing critical unmet medical needs within these therapeutic domains. Their current pipeline features promising candidates such as IBL-202, a dual-mechanism kinase inhibitor, and AUM302, which is being developed in partnership with AUM Biosciences. Inflection Biosciences is committed to advancing its innovative treatment options through robust research and development efforts.
How much funding has Inflection Biosciences raised?
Inflection Biosciences has raised a total of $785K across 1 funding round:
Private Equity
$785K
Private Equity (2015): $785K, investors not publicly disclosed
What's next for Inflection Biosciences?
With the recent infusion of capital, Inflection Biosciences is strategically positioned to accelerate the development of its therapeutic pipeline. The enterprise-level funding indicates a strong validation of the company's scientific approach and market potential. Future endeavors will likely concentrate on advancing IBL-202 and AUM302 through further preclinical and clinical trials, potentially expanding their therapeutic reach and solidifying their market presence in the competitive biopharmaceutical landscape. This strategic backing is pivotal for navigating the complex drug development pathway and achieving key regulatory milestones.
See full Inflection Biosciences company page
